Wallace DC, Singh G. Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. 1988;242:1427–30.

CAS  Google Scholar 

Chinnery PF, Johnson MA. The epidemiology of pathogenic mitochondrial DNA mutations. 2000;48:188–93.

CAS  Google Scholar 

Yu-Wai-Man P, et al. The epidemiology of Leber hereditary optic neuropathy in the North East of England. 2003;72:333–9.

CAS  Google Scholar 

Spruijt L, et al. Influence of mutation type on clinical expression of Leber hereditary optic neuropathy. 2006;141:676–82.

Google Scholar 

Yu-Wai-Man P, Chinnery PF. Leber hereditary optic neuropathy. 2000. https://www.ncbi.nlm.nih.gov/books/NBK1174/. Accessed April 27, 2022.

Rosenberg T, et al. Prevalence and genetics of Leber hereditary optic neuropathy in the Danish population. 2016;57:1370–5.

CAS  Google Scholar 

Chinnery PF, et al. Leber hereditary optic neuropathy: does heteroplasmy influence the inheritance and expression of the G11778A mitochondrial DNA mutation? 2001;98:235–243.

Jurkute N, et al. Clinical utility gene card for: inherited optic neuropathies including next-generation sequencing-based approaches. 2019;27:494–502.

CAS  Google Scholar 

Howell N. Leber hereditary optic neuropathy: respiratory chain dysfunction and degeneration of the optic nerve. 1998;38:1495–504.

CAS  Google Scholar 

Johns DR, et al. Leber’s hereditary optic neuropathy. Clinical manifestations of the 14484 mutation. 1993;111:495–498.

Carelli V, et al. International consensus statement on the clinical and therapeutic management of Leber hereditary optic neuropathy. 2017;37:371–81.

Google Scholar 

Newman NJ, et al. Visual outcomes in Leber hereditary optic neuropathy patients with the m.11778G>A (MTND4) mitochondrial DNA mutation. 2020;40:547–557.

Kirkman MA, et al. Gene-environment interactions in Leber hereditary optic neuropathy. 2009;132:2317–26.

Google Scholar 

Yen M, et al. Leber’s hereditary optic neuropathy: a multifactorial disease. 2006;25:381–96.

Google Scholar 

Jacobson DM, et al. Relative afferent pupillary defects in patients with Leber hereditary optic neuropathy and unilateral visual loss. 1998;126:291–5.

CAS  Google Scholar 

Newman NJ. Walsh and Hoyt’s clinical neuro-ophthalmology. Baltimore: Lippincott Williams & Wilkins; 2005.

Google Scholar 

Ruijin R, et al. A retrospective analysis of characteristics of visual field damage in patients with Leber’s hereditary optic neuropathy. 2016;5:843.

Google Scholar 

Shemesh A, et al. Leber hereditary optic neuropathy (LHON). 2021. https://www.ncbi.nlm.nih.gov/books/NBK482499/. Accessed April 27, 2022.

Nikoskelainen R, et al. The early phase in Leber hereditary optic atrophy. 1977;95:969–78.

CAS  Google Scholar 

Wang D, et al. Characterisation of thickness changes in the peripapillary retinal nerve fibre layer in patients with Leber’s hereditary optic neuropathy. 2021;105:1166–71.

Google Scholar 

Hedges TR, et al. The optical coherence tomographic profile of Leber hereditary optic neuropathy. 2016;40:107–12.

Google Scholar 

Matthews L, et al. MRI in Leber’s hereditary optic neuropathy: the relationship to multiple sclerosis. 2015;86:537–42.

Google Scholar 

Blanc C, et al. MRI of the optic nerves and chiasm in patients with Leber hereditary optic neuropathy. 2018;38:434–7.

Google Scholar 

Wallace SE, Bean LJH. Educational materials – genetic testing: current approaches. 2017. https://www.ncbi.nlm.nih.gov/books/NBK279899/#app5.Multigene_Panels. Accessed April 27, 2022.

Sundaramurthy A, et al. Next-generation sequencing of the complete mitochonfrial genome in individual with Leber hereditary optic neuropathy negative for the common pathogenic mitochondrial DNA mutations. 2020;61:5183.

Google Scholar 

Newman NJ. Treatment of Leber hereditary optic neuropathy. 2011;134:2447–50.

Google Scholar 

Lyseng-Williamson KA. Idebenone: a review in Leber’s hereditary optic neuropathy. 2016;76:805–813.

Klopstock T, et al. A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy (RHODOS). 2011;134:2677–86.

Google Scholar 

Carelli V, et al. Idebenone treatment in Leber’s hereditary optic neuropathy. 2011;134:188.

Google Scholar 

Thouin A, et al. Raised intraocular pressure as a potential risk factor for visual loss in Leber hereditary optic neuropathy. 2013;8:63446.

Google Scholar 

Biousse V, Newman NJ. The NORD guide to rare disorders. Philadelphia: Lippincott Williams & Wilkins; 2003.

Google Scholar 

Bower SP, et al. Cardiac arrhythmia and Leber’s hereditary optic neuropathy. 1992;339:1427–8.

CAS  Google Scholar 

Mackey D, et al. A variant of Leber hereditary optic neuropathy characterized by recovery of vision and by an unusual mitochondrial genetic etiology. 1991;51:1218–28.

Google Scholar 

Slone J, Huang T. The special considerations of gene therapy for mitochondrial diseases. 2020;5:7.

Google Scholar 

Sahel JA, et al. Gene therapies for the treatment of Leber hereditary optic neuropathy. 2021;61:195–208.

Google Scholar 

Guy J, et al. Gene therapy for Leber hereditary optic neuropathy: low- and medium- dose visual results. 2017;124:1621–34.

Google Scholar 

Lam BL, et al. Leber hereditary optic neuropathy gene therapy: adverse events and visual acuity results of all patient groups. Epub ahead of print. 2022.

•• Yuan J, et al. Seven-year follow-up of gene therapy for Leber’s hereditary optic neuropathy. 2020;8:1125–1127. This review conducted in China built on the prior safety profile demonstrated by Guy et al. in 2017, again demonstrated a favorable safety profile of the rAAV2/ND4 intravenous gene therapy over a 7-year period.

•• Yu-Wai-Man P, et al. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. 2020;12. The REVERSE trial was the first to directly measure efficacy of the rAAV2/ND4 intravenous gene therapy and demonstrated bilateral visual recovery after single eye injection. This suggested a crossing of the therapy to the fellow eye.

•• Newman NJ, et al. Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset. 2021;128:649–660. The RESCUE trial was similarly designed to REVERSE and demonstrated efficacy of the rAAV2/ND4 intravenous gene therapy in patients with less than 6 months of visual symptoms from LHON.

•• Efficacy & safety study of bilateral IVT injection of GS010 in LHON subjects due to the ND4 mutation for up to 1 year. ClinicalTrials.gov. 2019. https://www.clinicaltrials.gov/ct2/show/study/NCT03293524. Accessed 27 Apr 2022. The REFLECT trial is currently awaiting conclusion and reporting of data in literature. This trial builds on REVERSE and RESCUE’s findings of bilateral visual improvement by studying the efficacy of rAAV2/ND4 intravenous gene therapy injections into both eyes.

•• Biousse V, et al. Long-term follow-up after unilateral intravitreal gene therapy for Leber hereditary optic neuropathy: the RESTORE study. 2021;3:309–315. The RESTORE study demonstrated sustained treatment efficacy and safety of the rAAV2/ND4 intravenous gene therapy up from 96 weeks to 4.3 years.

Yu-Wai-Man P, et al. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. 2020;573.

Newman NJ. REFLECT trial: efficacy and safety of bilateral gene therapy for Leber hereditary optic neuropathy. In: NANOS 48th Annual Meeting On Demand Content. 2022. https://www.eventscribeapp.com/live/videoPlayer.asp?lsfp=N3ltTm9wUkFNVVErU1gxMk8rR3pqM3BUZTBBM3dYMDFJV201THFONzFwWT0=. Accessed April 27, 2022.

Vignal-Clermont C, et al. Safety of intravitreal gene therapy for treatment of subjects with Leber hereditary optic neuropathy due to mutations in the mitochondrial ND4 gene: the REVEAL study. 2021;35:201–214.